MEVIS MEDICAL SOLUTIONS AG (M3V.DE) Stock Fundamental Analysis

FRA:M3V • DE000A0LBFE4

24.8 EUR
+0.4 (+1.64%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, M3V scores 6 out of 10 in our fundamental rating. M3V was compared to 11 industry peers in the Health Care Technology industry. M3V gets an excellent profitability rating and is at the same time showing great financial health properties. M3V has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • M3V had positive earnings in the past year.
  • M3V had a positive operating cash flow in the past year.
  • Each year in the past 5 years M3V has been profitable.
  • M3V had a positive operating cash flow in each of the past 5 years.
M3V.DE Yearly Net Income VS EBIT VS OCF VS FCFM3V.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.22%, M3V belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Return On Equity of M3V (25.58%) is better than 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 14.00%, M3V belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for M3V is significantly above the industry average of 8.41%.
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROIC 14%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
M3V.DE Yearly ROA, ROE, ROICM3V.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • M3V has a better Profit Margin (26.87%) than 90.91% of its industry peers.
  • In the last couple of years the Profit Margin of M3V has declined.
  • With an excellent Operating Margin value of 23.58%, M3V belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • In the last couple of years the Operating Margin of M3V has declined.
  • The Gross Margin of M3V (97.12%) is better than 81.82% of its industry peers.
  • M3V's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
M3V.DE Yearly Profit, Operating, Gross MarginsM3V.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M3V is creating value.
  • The number of shares outstanding for M3V remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, M3V has about the same amount of shares outstanding.
  • M3V has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
M3V.DE Yearly Shares OutstandingM3V.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
M3V.DE Yearly Total Debt VS Total AssetsM3V.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 4.61 indicates that M3V is not in any danger for bankruptcy at the moment.
  • M3V has a better Altman-Z score (4.61) than 90.91% of its industry peers.
  • There is no outstanding debt for M3V. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.61
ROIC/WACC1.88
WACC7.45%
M3V.DE Yearly LT Debt VS Equity VS FCFM3V.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.3 Liquidity

  • M3V has a Current Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.52, M3V perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
  • M3V has a Quick Ratio of 1.52. This is a normal value and indicates that M3V is financially healthy and should not expect problems in meeting its short term obligations.
  • M3V's Quick ratio of 1.52 is fine compared to the rest of the industry. M3V outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.52
Quick Ratio 1.52
M3V.DE Yearly Current Assets VS Current LiabilitesM3V.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • M3V shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.41%.
  • The earnings per share for M3V have been decreasing by -10.74% on average. This is quite bad
  • Looking at the last year, M3V shows a decrease in Revenue. The Revenue has decreased by -2.14% in the last year.
  • The Revenue has been decreasing by -1.25% on average over the past years.
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
M3V.DE Yearly Revenue VS EstimatesM3V.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M3V.DE Yearly EPS VS EstimatesM3V.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.92, which indicates a very decent valuation of M3V.
  • Based on the Price/Earnings ratio, M3V is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.97. M3V is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.92
Fwd PE N/A
M3V.DE Price Earnings VS Forward Price EarningsM3V.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 63.64% of the companies in the same industry are more expensive than M3V, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, M3V is valued a bit cheaper than 63.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.87
EV/EBITDA 9.16
M3V.DE Per share dataM3V.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The excellent profitability rating of M3V may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • M3V has a Yearly Dividend Yield of 3.86%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.30, M3V pays a bit more dividend than its industry peers.
  • M3V's Dividend Yield is rather good when compared to the S&P500 average which is at 1.79.
Industry RankSector Rank
Dividend Yield 3.86%

5.2 History

  • The dividend of M3V is nicely growing with an annual growth rate of 24.89%!
Dividend Growth(5Y)24.89%
Div Incr Years0
Div Non Decr Years0
M3V.DE Yearly Dividends per shareM3V.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 107.89% of the earnings are spent on dividend by M3V. This is not a sustainable payout ratio.
  • M3V's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP107.89%
EPS Next 2YN/A
EPS Next 3YN/A
M3V.DE Yearly Income VS Free CF VS DividendM3V.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
M3V.DE Dividend Payout.M3V.DE Dividend Payout, showing the Payout Ratio.M3V.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MEVIS MEDICAL SOLUTIONS AG

FRA:M3V (2/13/2026, 7:00:00 PM)

24.8

+0.4 (+1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)01-29
Earnings (Next)05-25
Inst Owners23.29%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.14M
Revenue(TTM)16.97M
Net Income(TTM)4.56M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.86%
Yearly Dividend2.7
Dividend Growth(5Y)24.89%
DP107.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 9.92
Fwd PE N/A
P/S 2.66
P/FCF 15.87
P/OCF 14.35
P/B 2.53
P/tB 2.53
EV/EBITDA 9.16
EPS(TTM)2.5
EY10.08%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.56
FCFY6.3%
OCF(TTM)1.73
OCFY6.97%
SpS9.32
BVpS9.79
TBVpS9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number23.47
Profitability
Industry RankSector Rank
ROA 17.22%
ROE 25.58%
ROCE 19.88%
ROIC 14%
ROICexc 20.72%
ROICexgc 20.72%
OM 23.58%
PM (TTM) 26.87%
GM 97.12%
FCFM 16.76%
ROA(3y)19.91%
ROA(5y)19.35%
ROE(3y)32.29%
ROE(5y)30.88%
ROIC(3y)17.15%
ROIC(5y)17.35%
ROICexc(3y)27.89%
ROICexc(5y)26.51%
ROICexgc(3y)27.89%
ROICexgc(5y)26.51%
ROCE(3y)24.36%
ROCE(5y)24.64%
ROICexgc growth 3Y-4.16%
ROICexgc growth 5Y-6.12%
ROICexc growth 3Y-4.16%
ROICexc growth 5Y-6.1%
OM growth 3Y-4.71%
OM growth 5Y-9.81%
PM growth 3Y-1.4%
PM growth 5Y-9.66%
GM growth 3Y-0.07%
GM growth 5Y-0.07%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 227.51%
Cap/Sales 1.78%
Interest Coverage 250
Cash Conversion 76.1%
Profit Quality 62.38%
Current Ratio 1.52
Quick Ratio 1.52
Altman-Z 4.61
F-Score4
WACC7.45%
ROIC/WACC1.88
Cap/Depr(3y)151.22%
Cap/Depr(5y)111.1%
Cap/Sales(3y)0.98%
Cap/Sales(5y)0.77%
Profit Quality(3y)80.13%
Profit Quality(5y)97.8%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.41%
EPS 3Y0.13%
EPS 5Y-10.74%
EPS Q2Q%-38.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.14%
Revenue growth 3Y1.53%
Revenue growth 5Y-1.25%
Sales Q2Q%-7.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.41%
EBIT growth 3Y-3.25%
EBIT growth 5Y-10.94%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.74%
FCF growth 3Y-32.08%
FCF growth 5Y-14.82%
OCF growth 1Y-46.25%
OCF growth 3Y-29.89%
OCF growth 5Y-13.63%

MEVIS MEDICAL SOLUTIONS AG / M3V.DE FAQ

What is the ChartMill fundamental rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to M3V.DE.


What is the valuation status for M3V stock?

ChartMill assigns a valuation rating of 5 / 10 to MEVIS MEDICAL SOLUTIONS AG (M3V.DE). This can be considered as Fairly Valued.


How profitable is MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

MEVIS MEDICAL SOLUTIONS AG (M3V.DE) has a profitability rating of 8 / 10.


What is the financial health of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) stock?

The financial health rating of MEVIS MEDICAL SOLUTIONS AG (M3V.DE) is 8 / 10.